PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.

PROCEPT BioRobotics Corporation

PROCEPT BioRobotics develops and manufactures the AquaBeam Robotic System for aquablation therapy, a treatment for benign prostatic hyperplasia (BPH).

PROCEPT BioRobotics

PROCEPT BioRobotics is a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology. We develop, manufacture and sell the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally-invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. Our proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience.

Armentum Partners

CIBC Innovation Banking

Novo Holdings

Perceptive Advisors

Viking Global Investors

CPMG

T. Rowe Price

Duquesne Family Office

Fidelity

Fidelity Management and Research Company

Say hello to Barry Templin, a rockstar on our executive leadership team! With over 20 years of experience in clinical research, engineering, and market development, Barry’s expertise is transforming patient care.

From leading the game-changing PROSPECT study at Abbott Vascular to driving innovation at CardioKinetix, Barry’s journey has been nothing short of impressive. He started in engineering at GE Aircraft Engines and Guidant, and then transitioned to key clinical roles at Guidant and Abbott.

Barry holds a BS in Mechanical Engineering from Rose-Hulman Institute of Technology, and an MBA from Duke. 

We’re lucky to have Barry’s talent and passion fueling our mission to innovate and improve lives.

#Leadership #MedicalDevices

When Ed began experiencing #BPH symptoms, he was told, "Welcome to the club," but had no desire to be a part of it. 

Thanks to #Aquablation therapy, he experienced immediate and lasting symptom relief. https://bit.ly/3tFJM6X

Not all patients will experience the same results

Aquablation therapy now has 5-year results from two pivotal studies that demonstrate the reproducibility of Aquablation therapy to deliver significant symptom relief while preserving sexual function no matter the size of the patient’s prostate,” said Sham Shiblaq, EVP and Chief Commercial Officer of PROCEPT BioRobotics.
These impressive results are further validated by the growing number of hospitals and surgeons adopting Aquablation as their new standard of care for BPH treatment. Discover the advantages of #AquablationTherapy for managing #BPH patients. Explore the Five-Year data from the WATER II study: https://lnkd.in/dFBwzBfJ
#ClinicalStudy #BPHTreatment

Ever wondered why your fellow urologists are raving about Aquablation therapy? 
Catch Episode 103 of the Prostate Health Podcast! Dr. Jennifer E. Lloyd-Harris dives deep into why she chose to adopt this groundbreaking robotic waterjet technology in her practice. 
Discover what makes Aquablation therapy a game-changer for BPH treatment and why you should consider offering it to your patients.
#ProstateHealthPodcast #AquablationTherapy 
https://bit.ly/4cCXzN0

Ever wondered what’s going on with your plumbing? A normal prostate lets urine flow smoothly, but an enlarged prostate can turn that into a tricky business. 
Think of benign prostatic hyperplasia (BPH) as a friendly but overgrown neighbor—it’s not cancer, but it can cause some serious blockages! Left unchecked, it might lead to bladder or kidney issues.
#ProstateHealth #BPH

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover	0.10 -	0.06 38.44%	0.10 66.97%	0.24 137.08%	0.34 38.76%
cash conversion cycle	302.59 -	327.00 8.07%	265.35 18.85%	258.61 2.54%	276.77 7.02%
cash per share	1.25 -	2.85 127.75%	18.47 548.02%	5.00 72.94%	5.44 8.93%
company equity multiplier	-0.43 -	-0.69 59.80%	1.26 283.20%	1.57 24.39%	1.44 8.16%
days of inventory outstanding	303.00 -	304.18 0.39%	257.88 15.22%	274.68 6.51%	222.76 18.90%
days of payables outstanding	65.44 -	50.45 22.91%	39.80 21.10%	90.37 127.07%	75.64 16.30%
days of sales outstanding	65.02 -	73.26 12.67%	47.26 35.49%	74.31 57.22%	129.65 74.47%
dividend yield
ebit per revenue	-7.06 -	-6.19 12.25%	-1.57 74.64%	-1.08 31.51%	-0.80 25.51%
ebt per ebit	0.96 -	1.11 15.08%	1.11 0.37%	1.08 2.30%	0.97 10.15%
effective tax rate	-0.02 -	-0.10 511.41%	-0.04 57.18%	-0.07 74.47%
enterprise value multiple	-33.94 -	-31.89 6.01%	-3.00 90.60%	-21.60 620.66%	-17.11 20.78%
fixed asset turnover	0.75 -	0.60 19.87%	4.14 593.10%	2.33 43.64%	2.78 19.10%
free cash flow per share	-1.53 -	-1.38 9.72%	-3.51 154.26%	-1.87 46.79%	-2.82 50.73%
gross profit margin	-0.31 -	-0.16 46.78%	0.46 382.99%	0.49 7.42%	0.52 5.52%
interest coverage	-60.15 -	-9.09 84.89%	-9.32 2.60%	-15.57 67.07%	-27.33 75.45%
inventory turnover	1.20 -	1.20 0.39%	1.42 17.95%	1.33 6.11%	1.64 23.31%
long term debt to capitalization	-0.19 -	-0.36 87.44%	0.16 145.15%	0.28 69.48%	0.15 44.02%
net income per ebt	1.02 -	1.10 8.13%	1.04 5.14%	1.07 3.02%	1 6.87%
net profit margin	-6.91 -	-7.55 9.18%	-1.81 76.03%	-1.25 31.06%	-0.78 37.67%
operating cash flow per share	-1.30 -	-1.38 5.45%	-3.48 152.87%	-1.81 47.96%	-2.29 26.24%
operating cycle	368.03 -	377.45 2.56%	305.15 19.15%	348.99 14.37%	352.41 0.98%
operating profit margin	-7.06 -	-6.19 12.25%	-1.57 74.64%	-1.08 31.51%	-0.80 25.51%
payables turnover	5.58 -	7.24 29.72%	9.17 26.75%	4.04 55.96%	4.83 19.48%
pretax profit margin	-6.80 -	-6.87 0.97%	-1.74 74.73%	-1.16 33.08%	-0.78 33.07%
price fair value	-9.79 -	-8.06 17.72%	1.54 119.15%	9.36 506.48%	7.05 24.63%
receivables turnover	5.61 -	4.98 11.25%	7.72 55.01%	4.91 36.39%	2.82 42.68%
return on assets	-0.69 -	-0.46 32.78%	-0.19 59.97%	-0.30 63.44%	-0.26 13.51%
return on capital employed	-0.79 -	-0.43 45.63%	-0.17 60.63%	-0.29 74.46%	-0.30 3.29%
return on equity	0.30 -	0.32 7.41%	-0.23 173.33%	-0.47 103.31%	-0.38 20.57%
total debt to capitalization	-0.22 -	-0.43 91.05%	0.17 139.41%	0.28 67.29%	0.16 43.62%

COM:PROCEPT-BIOROBOTICS

PROCEPT BioRobotics

Last Close

94.45

22/11 21:00

Market Cap

3.35B

Beta: -

Volume Today

361.21K

Avg: -

Preview